Vitamin D3 Levels in COVID-19 Outpatients From Western Mexico: Clinical Correlation and Effect of Its Supplementation
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 42
- 试验地点
- 2
- 主要终点
- Baseline levels of serum vitamin D in COVID-19 patients
研究概览
简要总结
The immunomodulatory effects of vitamin D are known to be beneficial in viral infections, it is also known that its deficiency is associated with a worse prognosis of COVID-19. This study aimed to determine the baseline vitamin D serum concentrations in asymptomatic or mildly symptomatic COVID-19 outpatients, as well as to evaluate the effects of supplementation with 10,00 IU/daily of vitamin D3 and its relationship with biochemical parameters and clinical features.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Baseline levels of serum vitamin D in COVID-19 patients
时间窗: At baseline
Evaluate serum levels of 25(OH)D (ng/mL) in patients with covid-19 from western Mexico
Correlation between transferrin and vitamin D serum levels in COVID-19 patients
时间窗: At baseline
Serum levels of transferrin (mg/dL) will be measured at baseline and correlated with levels of 25(OH)D (ng/mL) in patients with covid-19 from western Mexico
Correlation between D-dimer and vitamin D serum levels in COVID-19 patients
时间窗: At baseline
Serum levels of D-dimer (ng/mL) will be measured at baseline and correlated with levels of 25(OH)D (ng/mL) in patients with covid-19 from western Mexico
Correlation between ferritin and vitamin D serum levels in COVID-19 patients
时间窗: At baseline
Serum levels of ferritin (ng/mL) will be measured at baseline and correlated with levels of 25(OH)D (ng/mL) in patients with covid-19 from western Mexico
Effects of vitamin D3 supplementation on COVID-19 patients
时间窗: After 14 days of supplementation
Serum levels of 25(OH)D (ng/mL) will be determined in the intervention group after 14 days of Vitamin D3 supplementation
次要结局
未报告次要终点
研究者
Jose Francisco Munoz Valle
Provost of the University Center of Health Sciences
University of Guadalajara